David Weild IV
About David Weild IV
David Weild IV (age 68) is an independent director of High Roller Technologies, Inc. (ROLR), serving since the company’s October 2024 IPO after advising the company from September 2022 to October 2024; he is Chair of the Audit Committee and qualifies as an SEC “audit committee financial expert.” He is founder, chairman, and CEO of Weild & Co., Inc. (parent of investment banking firm Weild Capital, LLC); formerly Vice Chairman at Nasdaq, President of PrudentialFinancial.com, and Head of Corporate Finance & Equity Capital Markets at Prudential Securities. He holds an MBA from NYU Stern and a BA from Wesleyan University, and is recognized for capital markets policy leadership as a principal architect of the JOBS Act.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Nasdaq | Vice Chairman | Not disclosed | Senior exchange leadership; market structure expertise |
| PrudentialFinancial.com | President | Not disclosed | Digital leadership for Prudential |
| Prudential Securities, Inc. | Head of Corporate Finance & Equity Capital Markets | Not disclosed | ECM leadership; IPOs and financings |
| Helium.com | Director | Sep 2010 – Jun 2011 | Board member through sale to R.R. Donnelley |
| Tuesday’s Children (9/11 charity) | Director; Chairman; Chairman Emeritus | 2003 – late 2016 | Non-profit governance leadership |
External Roles
| Organization | Role | Tenure | Notes / Committees |
|---|---|---|---|
| INX, LTD | Director | Current | Public company board service |
| BioSig Technologies, Inc. | Director | May 2015 – Feb 2024 | Public company board service |
| PAVmed | Director | Prior (dates not disclosed) | Public company board service |
| Scopus BioPharma | Director | Prior (dates not disclosed) | Public company board service |
| Dignity Beyond Borders | Director | Recently joined | Non-profit board service |
| Nasdaq-listed company (unspecified) | Audit Committee Chair | Prior (unspecified) | Audit chair experience |
Board Governance
- Independence: Determined independent under SEC and NYSE American rules.
- Committees: Audit (Chair: David Weild; members: Weild, Britt, Martensson), Compensation (members: Britt [Chair], Martensson, Weild), Nominating & Governance (members: Martensson [Chair], Britt, Weild).
- Audit Committee expertise: Weild qualifies as “audit committee financial expert” and meets NYSE American financial sophistication requirements.
- Attendance: In 2024, the board held 3 meetings; each director attended ≥75% of board and committee meetings on which they served.
- Executive sessions: Each regular board meeting includes executive sessions without employee directors; independent directors meet in executive session at least annually.
Fixed Compensation
| Component | Amount | Period / Terms | Notes |
|---|---|---|---|
| Fees Earned (Cash) | $6,000 | FY 2024 | As reported in director compensation table |
| Annual Director Retainer | $36,000 | Effective July 1, 2024 | Non-officer directors; payable annually |
| Committee Chair – Audit | $15,000 | Annual; payable quarterly | Applies to Weild (Audit Chair) |
| Committee Member – Compensation | $5,000 | Annual; payable quarterly | Weild is a member |
| Committee Member – Nominating & Governance | $4,000 | Annual; payable quarterly | Weild is a member |
| Chairman of the Board Increment | $35,000 | Annual | Not applicable to Weild (Cribari is Chairman) |
Performance Compensation
| Award Type | Grant Details | Vesting / Metrics | Fair Value |
|---|---|---|---|
| Stock Options (Non-Employee Directors) | 15,000 options @ $5.20; 10-year term | Time-based; vests October 31, 2025; no performance metrics disclosed | $48,000 option award value (FY 2024 total for Weild) |
| Performance-based Elements (Directors) | None disclosed | No director-specific performance metrics tied to pay disclosed | None disclosed |
Equity Incentive Plan permits performance awards broadly, but director compensation disclosure shows only time-based option grants for non-employee directors; no director performance metrics are specified.
Other Directorships & Interlocks
| Category | Details |
|---|---|
| Current public boards | INX, LTD |
| Prior public boards | BioSig Technologies (2015–Feb 2024), PAVmed, Scopus BioPharma |
| Private/non-profit boards | Dignity Beyond Borders; Tuesday’s Children (Director/Chairman/Chairman Emeritus) |
| Interlocks with ROLR counterparties | None disclosed |
| Compensation Committee Interlocks | None; no officers on ROLR compensation committee; no reciprocal interlocks with other issuers disclosed. |
Expertise & Qualifications
- Capital markets and governance: Extensive Wall Street and exchange leadership; recognized JOBS Act architect; frequent policy speaker at White House, Congress, SEC, OECD, G-20.
- Audit expertise: Designated “audit committee financial expert”; NYSE financial sophistication.
- Education: MBA (NYU Stern); BA (Wesleyan).
- Sector experience: Corporate finance, ECM, regulatory/legislative, small company financing.
Equity Ownership
| Instrument | Quantity | Strike | Vesting / Expiration | Status / Notes |
|---|---|---|---|---|
| Non-Employee Director Options | 15,000 | $5.20 | Vests Oct 31, 2025; 10-year term | Granted to each non-officer director; Weild included |
| Common shares (beneficial ownership) | Not disclosed | — | — | Not itemized for Weild in beneficial ownership table |
Governance Assessment
- Strengths: Independent director; Audit Committee Chair; audit financial expert designation; multi-committee service; ≥75% attendance in 2024; presence of Clawback Policy (Mar 2024); routine executive sessions—signals of governance rigor and oversight capacity.
- Compensation alignment: Modest cash fees; meaningful equity via 15,000 options with time-based vesting—aligns incentives with shareholder value creation without short-term performance gaming.
- Conflicts oversight: Audit Committee explicitly oversees related person transactions; board adopted a formal related person transaction policy on March 12, 2025—important given company-level related party dealings prior to policy adoption. Oversight responsibility sits with Weild’s committee.
- Watch items (company-level): Multiple related-party transactions among major shareholders and affiliates occurred pre-policy; continued rigorous Audit Committee review and enforcement is critical to investor confidence. No Weild-specific related party exposure disclosed.
No hedging/pledging or director-specific stock ownership guidelines disclosed; the company maintains an insider trading policy with blackout windows and MNPI controls.